fda compounding semaglutide enforcement news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA's GLP-1 decision kicks off

Avoid Agitation: Remember, peptides are not meant to be shaken

provide substantial contribution to interpretation of data, critically reviewed the manuscript, contribute an important intellectual content and gave final approval of the manuscript

Direct force can damage the peptide structure

Unlike injectable obesity drugs, which are peptides designed to mimic the appetite-controlling GLP-1 hormone, orforglipron is a small molecule pill that is easier to manufacture and package, said Kenneth Custer, president of Lilly's cardiometabolic health division

Until approval is granted, no legitimate private provider or doctor can supply Retatrutide

While we expect this pivot to continue to be disruptive in the short-term, we believe it will lead to long-term growth and refinement of a strategy that we could utilise out of the gate in the US market. With the new strategic direction and near-term disruption, management expects preliminary, unaudited revenue for the second quarter of 2025 to be approximately $3 million and an operating loss of approximately $7 million as compared to an operating loss of $9.3 million in the second quarter of 2024